Clinical Applications of Abagen™

Abagen, a patented anti-inflammatory peptide from blacklip abalone (Haliotis rubra) by Southern Ocean Biotech, offers a novel approach to managing inflammatory conditions driven by IL-6. Its validated efficacy in preclinical models, as detailed in patent WO 2017/124149 and Suleria et al. (2017), makes it a compelling candidate for clinical research and therapeutic development, particularly for doctors and scientists exploring innovative treatments.

Rheumatoid Arthritis

In a collagen-induced arthritis (CIA) mouse model, Abagen demonstrated remarkable anti-inflammatory effects. Prophylactic administration (100-500 mg/kg/day) reduced arthritis clinical scores by up to 50% (p<0.0001), with significant decreases in toe, paw, and carpus swelling and deformity (Patent WO 2017/124149, Figures 7-8). Therapeutic dosing also lowered synovitis scores (p<0.01) and IL-6 levels (p<0.01), as shown in Figures 9 and 11. These findings suggest Abagen could serve as a prophylactic or therapeutic agent for rheumatoid arthritis, targeting the IL-6 pathways central to its pathology, a potential reinforced by Suleria et al. (2017).

Other IL-6 Mediated Conditions

Beyond rheumatoid arthritis, Abagen’s ability to suppress IL-6 and inflammation opens doors to broader applications:

  • Inflammatory Bowel Disease (IBD):
    Potential to reduce chronic gut inflammation, such as in ulcerative colitis and Crohn’s disease, where IL-6 plays a role (Patent WO 2017/124149; Suleria et al., 2017).

  • Psoriasis & Eczema:
    May alleviate skin inflammation linked to elevated IL-6, offering a natural therapeutic option (Patent WO 2017/124149).

  • Autoimmune Diseases:
    Broad applicability in IL-6-driven conditions like systemic lupus erythematosus or transplant rejection (Patent WO 2017/124149).

Next Steps for Clinical Research

Abagen’s preclinical success paves the way for human trials to confirm its efficacy, safety, and optimal dosing. Its protein-enriched composition and natural marine origin make it an attractive candidate for pharmaceutical development by Southern Ocean Biotech. Medical professionals interested in advancing this peptide into clinical practice are invited to collaborate with our team.

Be the First to Discover Abagen™

Subscribe for exclusive updates!
Get early access to information about Abagen™